USPTO Examiner BENAVIDES JENNIFER ANN - Art Unit 1675

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19364297FORMULATIONS OF ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATIONOctober 2025March 2026Allow400YesNo
18637522ANTI-PD-L1 ANTIBODY AND USE THEREOFApril 2024July 2025Allow1510NoNo
18631672ANTIBODIES BINDING PD-1 AND USES THEREOFApril 2024March 2025Allow1100YesNo
18441469BISPECIFIC PD-1 AND TIGIT BINDING PROTEINS AND USES THEREOFFebruary 2024November 2025Allow2110NoNo
18435815HUMAN ANTIBODIES TO ARTEMIN AND METHODS OF USE THEREOFFebruary 2024May 2025Allow1510NoNo
18423089METHODS OF TREATING TUMORSJanuary 2024October 2025Allow2131YesNo
18417708MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORSJanuary 2024September 2025Allow2010YesNo
18537578METHODS FOR TREATING PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIADecember 2023June 2025Abandon1801NoNo
18516397COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1November 2023March 2026Abandon2820NoNo
18493744ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEINOctober 2023July 2025Abandon2010YesNo
18492028ENGINEERED ANTI-IL-2 ANTIBODIESOctober 2023December 2024Allow1300YesNo
18466722ILT-BINDING AGENTS AND METHODS OF USE THEREOFSeptember 2023May 2025Allow2010NoNo
18455181ANTI-CD200R1 ANTIBODIES AND METHODS OF USE THEREOFAugust 2023February 2025Allow1810NoNo
18446782SARS-COV-2 ANTIBODIES FOR TREATMENT AND PREVENTION OF COVID-19August 2023April 2025Abandon2010NoNo
18364285ILT3-BINDING AGENTS AND METHODS OF USE THEREOFAugust 2023August 2024Allow1300YesNo
18349438ANTI-MUC1 ANTIBODY-DRUG CONJUGATEJuly 2023December 2024Allow1710NoNo
18347361BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3July 2023April 2025Allow2120YesNo
18069317METHODS OF TREATING CANCER USING NEURONAL ACTIVITY INHIBITING AGENTSDecember 2022December 2024Allow2421YesNo
17913182BINDING MOLECULE HAVING NEUTRALIZING ACTIVITY AGAINST SARS-CORONAVIRUS-2September 2022October 2025Allow3700YesNo
17759800NOVEL LILRB2 ANTIBODIES AND USES THEREOFJuly 2022December 2025Allow4010YesNo
17795960ENGINEERED ANTI-IL-2 ANTIBODIESJuly 2022December 2024Allow2910YesNo
17873864NOVEL POLYPEPTIDES AND USES THEREOFJuly 2022February 2025Allow3151NoNo
17813122IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOFJuly 2022September 2025Allow3831YesNo
17812950DOSAGE REGIMESJuly 2022February 2026Abandon4310NoNo
17812159ANTI-GAL3 ANTIBODIES AND METHODS OF USEJuly 2022February 2025Abandon3141NoNo
17827630Sequences of anti-ecto-5'-nucleotidase antibodiesMay 2022November 2025Allow4110YesNo
17775942HUMAN MONOCLONAL ANTIBODIES TO HANTAVIRUS AND METHODS OF USE THEREFOREMay 2022September 2025Allow4120YesNo
17775706ANTI-HUMAN CRIPTO-1 ANTIBODYMay 2022October 2025Allow4110YesNo
17662573ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND METHODS OF USE THEREOFMay 2022December 2025Abandon4310NoNo
17775279METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATEMay 2022December 2025Abandon4301NoNo
17775167COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETINGMay 2022December 2025Allow4320YesNo
17718771ANTI AQP3 MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOFApril 2022December 2025Abandon4401NoNo
17716530METHOD FOR TREATING CANCER USING IMMUNE CHECKPOINT INHIBITORApril 2022April 2025Abandon3631NoNo
17763621HUMANIZED MONOCLONAL ANTIBODY FOR 2019 NOVEL CORONAVIRUS AND USE THEREOFMarch 2022August 2025Allow4110YesNo
17763113A NOVEL ANTI-PD-L1/ANTI-LAG-3 BISPECIFIC ANTIBODY AND USES THEREOFMarch 2022November 2025Abandon4410NoNo
17642674ZIKA ANTIBODIES AND THEIR USEMarch 2022November 2025Allow4411YesNo
17687558EPHA2 ANTIBODIESMarch 2022July 2024Allow2921YesNo
17686666ANTI-CD73 ANTIBODIES AND USE THEREOFMarch 2022August 2024Allow2931YesNo
17685423METHODS FOR THE TREATMENT OF GPPMarch 2022December 2024Abandon3321NoNo
17580547METHODS AND COMPOSITIONS RELATING TO ADENOSINE RECEPTORSJanuary 2022September 2024Allow3221YesNo
17625445NOVEL FUSION PROTEIN AND USE OF SAMEJanuary 2022October 2025Abandon4501NoNo
17562961Antibody Compositions and Methods of Use ThereofDecember 2021November 2024Abandon3531YesNo
17611318NOVEL MODIFIED IMMUNOGLOBULIN FC-FUSION PROTEIN AND USE THEREOFNovember 2021October 2025Allow4710YesNo
17508714METHOD FOR IMPROVING NEUROLOGICAL FUNCTION IN MPSI AND MPSII AND OTHER NEUROLOGICAL DISORDERSOctober 2021October 2025Abandon4811NoNo
17507618ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOFOctober 2021September 2025Abandon4701NoNo
17501846BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28October 2021August 2025Abandon4641NoNo
17416846FOOD AND ADDITIVE COMPOSITIONS, AND ALSO USES OF LIGNIN AND THE ADDITIVE COMPOSITIONJune 2021February 2026Abandon5641NoNo
17323884MAGEB2 BINDING CONSTRUCTSMay 2021January 2024Allow3211NoNo
17292888IMMUNOGENIC PEPTIDES WITH NEW OXIDOREDUCTASE MOTIFSMay 2021August 2025Abandon5211NoNo
17315061COMPOSITIONS AND METHODS FOR PREDICTING THERAPEUTIC OUTCOMEMay 2021August 2024Allow3911YesNo
17290961B-CELL ACTIVATING CD73 ANTIBODIESMay 2021November 2025Abandon5521NoNo
17244785METHODS OF TREATING MULTIPLE MYELOMAApril 2021October 2024Abandon4230NoYes
17232263DIAGNOSTIC AND THERAPEUTIC METHODS FOR KIDNEY CANCERApril 2021October 2025Abandon5421YesNo
17265506TREATMENT OF IMMUNE DISEASES BY MEANS OF THE ANTIBODY-MEDIATED NEUTRALIZATION OF SPECIFIC INTESTINAL BACTERIAFebruary 2021November 2024Abandon4630NoNo
17264760USE OF INTERLEUKIN-7 AND CHIMERIC ANTIGEN RECEPTOR (CAR)-BEARING IMMUNE EFFECTOR CELLS FOR TREATING TUMORJanuary 2021November 2025Abandon5740NoNo
17261245INHIBITION OF CYSTATINS FOR THE TREATMENT OF CHRONIC RHINOSINUSITISJanuary 2021June 2025Abandon5221NoNo
17131221IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2December 2020May 2025Allow5330YesNo
17252482METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCERDecember 2020August 2025Abandon5641NoNo
17251497BIOLUMINESCENT MARKERS OF NEURAL ACTIVITYDecember 2020May 2025Abandon5311NoNo
17116699Stabilized Formulations Containing Anti-CD20 x Anti-CD3 Bispecific AntibodiesDecember 2020June 2025Abandon5440NoYes
17112768FORMULATIONS OF ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATIONDecember 2020February 2026Allow6051YesYes
17055279ANTIBODIES AGAINST LIF AND DOSAGE FORMS THEREOFNovember 2020September 2025Abandon5841YesNo
17081356ANTIBODY CARRIER BASED ON GOLD NANOPARTICLE-APTAMER CONJUGATE AND METHOD OF PREPARING THE SAMEOctober 2020November 2025Abandon6071YesNo
17048508BINDING MOLECULESOctober 2020January 2025Abandon5110NoNo
17046341METHOD FOR TREATING AUTOIMMUNE DISEASEOctober 2020October 2025Abandon6031YesNo
16959378PEPTIDE IMMUNOGENS AND FORMULATIONS THEREOF TARGETING MEMBRANE-BOUND IgE FOR TREATMENT OF IgE MEDIATED ALLERGIC DISEASESJune 2020January 2025Allow5421YesNo
16955984ASSAY, METHOD AND TREATMENT OF ALPHA-SYNUCLEINOPATHIESJune 2020March 2026Abandon6060YesNo
16767189METHODS OF PREVENTING OR TREATING NEUROGENIC SHOCKMay 2020July 2025Abandon6051NoNo
16760899CD47 ANTIGEN-BINDING MOLECULESApril 2020November 2024Abandon5431NoNo
16781161METHOD FOR ACQUIRING INFORMATION ON ANALYTEFebruary 2020August 2025Abandon6050NoNo
16461430METHODS FOR TREATING PERIPHERAL NERVE INJURYMay 2019May 2022Abandon3651YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BENAVIDES, JENNIFER ANN.

Strategic Value of Filing an Appeal

Total Appeal Filings
4
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
4
(100.0%)
Filing Benefit Percentile
1.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BENAVIDES, JENNIFER ANN - Prosecution Strategy Guide

Executive Summary

Examiner BENAVIDES, JENNIFER ANN works in Art Unit 1675 and has examined 30 patent applications in our dataset. With an allowance rate of 20.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 54 months.

Allowance Patterns

Examiner BENAVIDES, JENNIFER ANN's allowance rate of 20.0% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BENAVIDES, JENNIFER ANN receive 3.00 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BENAVIDES, JENNIFER ANN is 54 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +36.1% benefit to allowance rate for applications examined by BENAVIDES, JENNIFER ANN. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.1% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.